Shanghai RAAS Blood Products (002252) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 was ¥2.14 billion, up 3.72% year-over-year, but year-to-date revenue fell 3.54% to ¥6.09 billion compared to the same period last year.

• Net profit attributable to shareholders in Q3 was ¥441 million, down 26.16% year-over-year; year-to-date net profit was ¥1.47 billion, down 19.97% year-over-year.

• Cash flow from operating activities increased 33.99% year-over-year to ¥691 million for the quarter.

Financial highlights

• Basic and diluted EPS for Q3 were ¥0.067, down 25.56% year-over-year; year-to-date EPS was ¥0.222, down 19.86%.

• Gross margin and operating income details not specified, but operating profit for the period was ¥1.74 billion, down from ¥2.26 billion last year.

• Total assets increased 13.05% to ¥38.02 billion at quarter-end.

• Shareholders’ equity rose 2.06% to ¥32.58 billion.

Outlook and guidance

• No explicit forward-looking guidance provided, but multiple rounds of share buybacks and controlling shareholder increases signal confidence in long-term value.